Table 1.
Demographic and sample collection information of HCWs and BA.1- or BA.4/5-wave patients
| Vaccinated HCWs (n = 15) | BA.1-wave hospitalized patients (n = 15) |
BA.4/5-wave first responders/household contacts (n = 20) | |
|---|---|---|---|
| Age in years at sample collection [median (range)] | 33 (26–61) | 57 (28–77) | 44 (27–58) |
| Gender [n (% of total)] | |||
| Male | 10 (66.7%) | 12 (80.0%) | 4 (20.0%) |
| Female | 5 (33.3%) | 3 (20.0%) | 15 (75.0%) |
| Sample collection window | Oct 2021–Feb 2022 | Jan 2022–Feb 2022 | Mar 2022–Sept 2022 |
| Type of vaccine [n (% of total)] | |||
| Unvaccinated | N/A | 6 (40.0%) | 17 (85.0%) |
| 3-dose Moderna | 3 (20.0%) | N/A | 2 (10.0%) |
| 3-dose Pfizer | 12 (80.0%) | 4 (26.7%) | 1 (5.0%) |
| 2-dose Moderna | N/A | 3 (20.0%) | N/A |
| 2-dose Pfizer | N/A | 2 (13.3%) | N/A |
| Sample collection timing [median (range)] | |||
| Days post third dose for recipients of 3 doses | 40 (21–86) | 166.5 (158–183) | 158 (64–183) |
| Days post diagnosis | N/A | 4 (1–7) | DNC |
| Prior SARS-CoV-2 infection confirmed by PCR [n (% of total)] | 2 (13.3%) | DNC | 2 (10.0%) |
Summary information for the HCW sera samples collected after 3 doses of mRNA vaccine is shown. In addition, summary information of the hospitalized BA.1-wave patients and first responder and household contacts testing positive for COVID-19 by PCR during the BA.4/5 wave is also provided. N/A means “not applicable” and DNC means “data not collected.”